将肿瘤浸润淋巴细胞纳入PREDICT预后模型以预测三阴性乳腺癌生存
本研究将间质肿瘤浸润淋巴细胞(sTILs)纳入PREDICT模型,构建PREDICT_sTILs,用于早期三阴性乳腺癌(TNBC)化疗决策。基于3698例患者数据,模型在5年和10年乳腺癌特异性生存预测中校准良好(O/E比分别为0.98和0.99),区分度AUC均为0.74,较原PREDICT模型能多识别低危和高危患者。
要点
- PREDICT_sTILs在早期TNBC中校准与区分度良好,5年O/E比0.98,10年0.99。
- 在10年风险阈值8%-15%下,每1000例未化疗患者多识别19-60例净真低危和3-10例净真高危。
- sTILs加入PREDICT有助于识别可安全免除化疗的低危TNBC患者。
核心结论
- 将sTILs加入PREDICT模型可改善早期TNBC化疗决策,尤其有助于识别可安全免除化疗的低危个体。
研究设计与样本
- 研究纳入1979至2017年诊断的3698例早期TNBC女性,来自两个合并队列,sTILs按国际指南评分,用于更新PREDICT 2.3版。
- PREDICT_sTILs为Cox回归模型,以sTILs和PREDICT预后指数为预测因子,结局为乳腺癌特异性生存。
- 采用留一区域交叉验证进行内部-外部验证,校准用观察与期望比(O/E比)评估,区分度用曲线下面积(AUC)评估。
- 通过决策曲线分析比较PREDICT_sTILs与PREDICT的临床价值,考察10年乳腺癌死亡风险阈值8%-15%下的净真高危和低危分类。
主要发现
- 3698例患者中,1806例接受化疗,1892例未接受化疗;化疗患者中位年龄50岁、肿瘤大小25 mm、1个阳性淋巴结,未化疗患者中位年龄55岁、肿瘤大小20 mm、0个阳性淋巴结。
- 5年和10年内分别有741和860例死于乳腺癌。
- PREDICT_sTILs内部-外部验证良好,5年合并O/E比为0.98(95%CI 0.69-1.41),10年为0.99(95%CI 0.72-1.35)。
- 5年和10年AUC分别为0.74(95%CI 0.72-0.77)和0.74(95%CI 0.70-0.78)。
- 在10年风险阈值8%-15%下,每1000例未化疗患者中,PREDICT_sTILs较PREDICT多识别19-60例净真低危患者和3-10例净真高危患者。
临床怎么用
- 对于早期TNBC患者,可将sTILs纳入PREDICT模型评估乳腺癌特异性生存,辅助化疗决策。
- 在10年乳腺癌死亡风险8%-15%阈值下,PREDICT_sTILs有助于识别可能安全免除化疗的低危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stromal tumor-infiltrating lymphocytes (sTILs) are a strong prognostic marker in patients with triple-negative breast cancer (TNBC). We aimed to incorporate sTILs into the PREDICT model for women with early-stage TNBC to guide chemotherapy decisions. PATIENTS AND METHODS: We included 3698 women with early-stage TNBC, diagnosed between 1979 and 2017, from two pooled cohorts with sTILs scored according to international guidelines to update PREDICT version 2.3. The updated model, PREDICT_sTILs, is a Cox regression model with sTILs and the PREDICT prognostic index as predictors and breast cancer-specific survival as the outcome. Internal-external validation was conducted using leave-one-region-out cross-validation, with calibration assessed by the observed-to-expected (O/E) ratio and discrimination by area under the curve (AUC). We compared the clinical values of PREDICT_sTILs and PREDICT through decision curve analysis, examining net true high-risk and low-risk classifications across risk thresholds of 10-year breast cancer mortality above 8%-15%. RESULTS: Among the 3698 patients, 1806 received chemotherapy while 1892 were chemotherapy-naïve. Chemotherapy-treated patients had a median age of 50 years, a tumor size of 25 mm, and one positive lymph node. The chemotherapy-naïve patients had a median age of 55 years, a tumor size of 20 mm, and 0 positive lymph nodes. Within 5 and 10 years, 741 and 860 deaths were attributed to breast cancer, respectively. PREDICT_sTILs showed strong internal-external validity, with comparable calibration and discrimination at both time points: pooled O/E ratios of 0.98 [95% confidence interval (CI) 0.69-1.41] at 5 years and 0.99 (95% CI 0.72-1.35) at 10 years, and AUCs of 0.74 (95% CI 0.72-0.77) and 0.74 (95% CI 0.70-0.78), respectively. Compared with PREDICT, PREDICT_sTILs identified 19-60 additional net true low-risk patients and 3-10 additional net true high-risk patients per 1000 chemotherapy-naïve patients at the risk thresholds of 8%-15% at 10 years. CONCLUSION: Adding sTILs to PREDICT improves its ability to inform chemotherapy decisions for early-stage patients with TNBC, especially in identifying low-risk individuals who may safely forgo chemotherapy.
引用
- Wang Y, Drubay D, Jonas SF, et al. Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival. Ann Oncol. 2026. PMID: 42025762. doi:10.1016/j.annonc.2026.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。